Literature DB >> 9949963

An MRSA outbreak in a urology ward and its association with Nd:YAG coagulation laser treatment of the prostate.

J W Jones1, A Carter, P Ewings, P J O'Boyle.   

Abstract

An outbreak of methicillin resistant Staphylococcus aureus (MRSA) involving 88 patients in a general urology ward is described. Symptomatic bacteraemia and epididymo-orchitis occurred in 10 and 8% of patients respectively. Patients had a particularly high risk of acquiring serious MRSA infection after endoscopic neodymium yttrium aluminium garnet (Nd:YAG) laser treatment of the prostate. Appreciation of the mode of transmission of MRSA, a programme of continuing education for all medical and nursing staff, simple changes in ward protocol and advances in surgical laser technique contributed to the control of the outbreak.

Entities:  

Mesh:

Year:  1999        PMID: 9949963     DOI: 10.1016/s0195-6701(99)90035-x

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  4 in total

1.  Indwelling catheterization, renal stones, and hydronephrosis are risk factors for symptomatic Staphylococcus aureus-related urinary tract infection.

Authors:  Hiroyuki Kitano; Norifumi Shigemoto; Yumiko Koba; Toshinori Hara; Kashiyama Seiya; Keitaro Omori; Katsumi Shigemura; Jun Teishima; Masato Fujisawa; Akio Matsubara; Hiroki Ohge
Journal:  World J Urol       Date:  2020-05-03       Impact factor: 4.226

2.  [Positive screening for MRSA--clinical consequences?].

Authors:  M Neumaier; I Kappstein; M A Scherer
Journal:  Unfallchirurg       Date:  2006-06       Impact factor: 1.000

3.  [Activity of antiseptic catheter lubricants against methicillin-resistant Staphylococcus aureus (MRSA)].

Authors:  P Faul
Journal:  Urologe A       Date:  2005-03       Impact factor: 0.639

4.  Methicillin-resistant Staphylococcus aureus (MRSA) in an Austrian urological department: 10 years experience covering 95.161 patients.

Authors:  Stefan Heidler; Friederike Asboth; Can Mert; Stephan Madersbacher
Journal:  World J Urol       Date:  2012-08-05       Impact factor: 4.226

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.